Avenacy to Attend 2026 DCAT Week
SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will attend DCAT Week from March 23-26, 2026 in New York City.
During DCAT Week, the Avenacy team will highlight its rapidly expanding differentiated portfolio, now comprised of twenty-six critical acute care medications and shortage products. The Company will also host meetings with potential customers and partners to discuss Avenacy’s strategic plans to continue market expansion through additional product launches. To request a meeting with a member of the Avenacy team, please reach out to [email protected].
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260316315025/en/
Media Contact
FTI Consulting
[email protected]
Source: Avenacy
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Board of Directors of TotalEnergies Reaffirms the Relevance of the Company’s Strategy and Its Confidence in the Governance & Management to Continue Its Implementation
- Anmodning om suspension i enkelte afdelinger under Investeringsforeningen Danske Invest
- Neuralia TMS Spotlights TMS Therapy Availability at Its Kardinya Location
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share